AF1q enhancement of γ irradiation-induced apoptosis by up-regulation of BAD expression via NF-κB in human squamous carcinoma A431 cells

Oncology Reports

Volumn 24, Issue 2, 2010, Pages 547-554

  Co, Ngai Na ^a   Tsang, Wing Pui ^a   Tsang, Tsun Yee ^a   Yeung, Chi Lam Au ^a   Yau, Pak Lun ^a   Kong, Siu Kai ^a   Kwok, Tim Tak ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

irradiation; Apoptosis; NF B; Squamous carcinoma

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN; PROTEIN AF1Q; PROTEIN BAD; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; BAD PROTEIN, HUMAN; MLLT11 PROTEIN, HUMAN; ONCOPROTEIN; PLASMA PROTEIN; PROTEIN BINDING; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GAMMA IRRADIATION; GENE REPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; SQUAMOUS CELL CARCINOMA; TRANSIENT TRANSFECTION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GAMMA RADIATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; RADIATION RESPONSE; TUMOR CELL LINE;

APOPTOSIS; BASE SEQUENCE; BCL-ASSOCIATED DEATH PROTEIN; BLOOD PROTEINS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; UP-REGULATION; PROTO-ONCOGENE PROTEINS;

EID: 77954368021     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000891     Document Type: Article

References (40)

1. Bouillet P and Strasser A: BH3-only proteins - evolutionarily conserved proapoptotic bcl-2 family members essential for initiating programmed cell death. J Cell Sci 115: 1567-1574, 2002.
2. Baliga B and Kumar S: Apaf-1/cytochrome c apoptosome: an essential initiator of caspase activation or just a sideshow? Cell Death Differ 10: 16-18, 2003.
3. Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, Datta SR, Greenberg ME, Licklider LJ, Lowell BB, Gygi SP and Korsmeyer SJ: BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424: 952-956, 2003.
4. Zha J, Harada H, Yang E, Jockel J and Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619-628, 1996.
5. Fernando R, Foster JS, Bible A, Ström A, Pestell RG, Rao M, Saxton A, Baek SJ, Yamaguchi K, Donnell R, Cekanova M and Wimalasena J: Breast cancer cell proliferation is inhibited by BAD: regulation of cyclin D1. J Biol Chem 282: 28864-28873, 2007.
6. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
7. Yang E, Zha J, Jockel J, Boise LH, Thompson CB and Korsmeyer SJ: Bad, a heterodimeric partner for bcl-XL and bcl-2, displaces bax and promotes cell death. Cell 80: 285-291, 1995.
8. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T and Korsmeyer SJ: BCL-2, BCL-X(L) sequester BH3 domainonly molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705-711, 2001.
9. Kelekar A, Chang BS, Harlan JE, Fesik SW and Thompson CB: Bad is a BH3 domain-containing protein that forms an inactivating dimer with bcl-XL. Mol Cell Biol 17: 7040-7046, 1997. (Pubitemid 27505933)
10. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, Strasser A, Kluck RM, Adams JM and Huang DC: Apoptosis initiated when BH3 ligands engage multiple bcl-2 homologs, not bax or bak. Science 315: 856-859, 2007.
11. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR and Newmeyer DD: BH3 domains of BH3-only proteins differentially regulate bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17: 525-535, 2005.
12. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB and Korsmeyer SJ: tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 14: 2060-2071, 2000.
13. Jiang P, Du W, Heese K and Wu M: The bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Mol Cell Biol 26: 9071-9082, 2006.
14. Bonni A, Brunet A, West AE, Datta SR, Takasu MA and Greenberg ME: Cell survival promoted by the ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286: 1358-1362, 1999.
15. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997. (Pubitemid 27456390)
16. Harada H, Becknell B, Wilm M, Mann M, Huang LJ, Taylor SS, Scott JD and Korsmeyer SJ: Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell 3: 413-422, 1999.
17. Zhou XM, Liu Y, Payne G, Lutz RJ and Chittenden T: Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem 275: 25046-25051, 2000.
18. Tse W, Meshinchi S, Alonzo TA, Stirewalt DL, Gerbing RB, Woods WG, Appelbaum FR and Radich JP: Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood 104: 3058-3063, 2004.
19. Tse W, Zhu W, Chen HS and Cohen A: A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. Blood 85: 650-656, 1995.
20. Tse W, Joachim Deeg H, Stirewalt D, Appelbaum FR, Radich J and Gooley T: Increased AF1q gene expression in high-risk myelodysplastic syndrome. Br J Haematol 128: 218-220, 2005.
21. Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ and Shao ZM: Identification of the functional role of AF1Q in the progression of breast cancer. Breast Cancer Res Treat 111: 65-78, 2008.
22. Li DQ, Hou YF, Wu J, Chen Y, Lu JS, Di GH, Ou ZL, Shen ZZ, Ding J and Shao ZM: Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. Eur J Cancer 42: 3274-3286, 2006.
23. Jacques C, Baris O, Prunier-Mirebeau D, Savagner F, Rodien P, Rohmer V, Franc B, Guyetant S, Malthiery Y and Reynier P: Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J Clin Endocrinol Metab 90: 2314-2320, 2005.
24. Co NN, Tsang WP, Wong TW, Cheung HH, Tsang TY, Kong SK and Kwok TT: Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway. Mol Cancer Ther 7: 3160-3168, 2008.
25. Mameli G, Astone V, Khalili K, Serra C, Sawaya BE and Dolei A: Regulation of the syncytin-1 promoter in human astrocytes by multiple sclerosis-related cytokines. Virology 362: 120-130, 2007.
26. Li D, Ueta E, Kimura T, Yamamoto T and Osaki T: Reactive oxygen species (ROS) control the expression of bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci 95: 644-650, 2004.
27. Hornyak TJ, Jiang S, Guzman EA, Scissors BN, Tuchinda C, He H, Neville JD and Strickland FM: Mitf dosage as a primary determinant of melanocyte survival after ultraviolet irradiation. Pigment Cell Melanoma Res 22: 307-318, 2009.
28. Chirico F, Fumelli C, Marconi A, Tinari A, Straface E, Malorni W, Pellicciari R and Pincelli C: Carboxyfullerenes localize within mitochondria and prevent the UVB-induced intrinsic apoptotic pathway. Exp Dermatol 16: 429-436, 2007.
29. Pardo OE, Arcaro A, Salerno G, Raguz S, Downward J and Seckl MJ: Fibroblast growth factor-2 induces translational regulation of bcl-XL and bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem 277: 12040-12046, 2002.
30. Slater AF, Kimland M, Jiang SA and Orrenius S: Constitutive nuclear NF kappa B/rel DNA-binding activity of rat thymocytes is increased by stimuli that promote apoptosis, but not inhibited by pyrrolidine dithiocarbamate. Biochem J 312 (Pt 3): 833-838, 1995. (Pubitemid 3009851)
31. Siervo-Sassi RR, Marrangoni AM, Feng X, Naoumova N, Winans M, Edwards RP and Lokshin A: Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett 190: 61-72, 2003.
32. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N and Tschopp J: TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7: 831-836, 1997.
33. Catz SD and Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20: 7342-7351, 2001.
34. Lee HH, Dadgostar H, Cheng Q, Shu J and Cheng G: NF-kappaB-mediated up-regulation of bcl-x and bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 96: 9136-9141, 1999.
35. Chen F, Demers LM, Vallyathan V, Lu Y, Castranova V and Shi X: Involvement of 5'-flanking kappaB-like sites within bcl-x gene in silica-induced bcl-x expression. J Biol Chem 274: 35591-35595, 1999.
36. Grumont RJ, Rourke IJ and Gerondakis S: Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 13: 400-411, 1999.
37. Zong WX, Edelstein LC, Chen C, Bash J and Gelinas C: The prosurvival bcl-2 homolog bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 13: 382-387, 1999. (Pubitemid 29108753)
38. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, Miano MP, De Nigris F, Casalino L, Curcio F, Santoro M and Fusco A: Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 15: 1987-1994, 1997.
39. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM and Sonenshein GE: Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952-2960, 1997.
40. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD and Scheidereit C: Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 14: 399-402, 2000. (Pubitemid 30142862)